Alphamab Oncology, Institut Pasteur Shanghai To Co-develop COVID-19 Neutralizing Ab
Alphamab Oncology has announced that Jiangsu Alphamab Biopharmaceuticals Co., Ltd., a wholly-owned subsidiary of the Company, has entered a partnership agreement with Institut Pasteur of Shanghai, Chinese Academy of Sciences on the co-development, manufacturing and commercialization of therapeutic antibody (Ab) for Corona Virus Disease 2019 (COVID-19) worldwide.
This cooperation will fully leverage not only Institut Pasteur Shanghai 's prowess in research and development, and prior research findings in the area of infectious diseases, but also Alphamab Oncology's strong R&D and its proprietary Mixed Antibodies Platform, to develop COVID-19 neutralizing antibody with good safety and high neutralizing activity, complete clinical trials soon to provide antibody treatment options, effectively improve the prevention capabilities, reduce the mortality rate, and contribute to disease prevention and control for China and the world. Meanwhile, Pasteur's global R&D network could also help expedite the completion of clinical trial.
According to the agreement, Alphamab Oncology and Institut Pasteur Shanghai will form a joint project team. Alphamab Oncology is responsible for providing its proprietary Mixed Antibodies Platform, constructing humanized antibodies and recombinant engineered cell lines, carrying out PK study, clinical trials, manufacturing, and commercialization. Institut Pasteur Shanghai is responsible for the comprehensive analysis of neutralizing activity of COVID-19 antibodies.